Online citations, reference lists, and bibliographies.
← Back to Search

Physiologically Based Pharmacokinetic Modeling

H. Clewell, M. Reddy, T. Lavé, M. Andersen
Published 2010 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
In the pharmaceutical area, the use of physiologically based pharmacokinetic (PBPK) models was limited in drug development due to the perceived mathematical complexity of the models and the labor-intensive input data required. However, advances in the prediction of hepatic metabolism and tissue distribution from in vitro and in silico data have made the use of these models more attractive, providing the opportunity to gain mechanistic insight into the compound's properties. This article provides information necessary to understanding the application of PBPK models in preclinical drug development and advances in the available tools. Keywords: physiologically based pharmacokinetic (PBPK) models; drug development; preclinical data; drug metabolism
This paper references
10.1126/SCIENCE.109.2841.579
Quantitative Relations in the Physiological Constitutions of Mammals.
E. Adolph (1949)
10.1002/JPS.2600590203
Preliminary model for methotrexate pharmacokinetics.
K. B. Bischoff (1970)
10.1002/jps.2600600803
Methotrexate pharmacokinetics.
K. B. Bischoff (1971)
10.1016/0006-2952(81)90180-5
Dose-dependent kinetics of all-trans-retinoic acid in rats. Plasma levels and excretion into bile, urine, and faeces.
B. N. Swanson (1981)
10.3109/10408448109059563
Saturable metabolism and its relationship to toxicity.
M. Andersen (1981)
10.1002/JPS.2600710704
Concentration-dependent disappearance of fluorouracil from peritoneal fluid in the rat: experimental observations and distributed modeling.
J. Collins (1982)
10.1002/JPS.2600710421
Determination of tissue to blood partition coefficients in physiologically-based pharmacokinetic studies.
G. Lam (1982)
10.1002/JPS.2600721003
Physiologically based pharmacokinetic modeling: principles and applications.
L. E. Gerlowski (1983)
10.1016/0041-008X(87)90281-X
Physiologically based pharmacokinetics and the risk assessment process for methylene chloride.
M. Andersen (1987)
10.1016/0378-4274(88)90024-0
Cisplatin pharmacokinetics: applications of a physiological model.
F. Farris (1988)
10.1016/0041-008X(89)90149-X
Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid.
J. Fisher (1989)
10.1016/0041-008X(92)90194-W
A physiologically based kinetic model of rat and mouse gestation: disposition of a weak acid.
E. O'flaherty (1992)
10.1002/JPS.2600810630
Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development
C. Peck (1992)
10.1093/JNCI/84.17.1332
Dose-dependent pharmacokinetics of all-trans-retinoic acid.
P. Adamson (1992)
10.1111/J.1539-6924.1993.TB00726.X
Modeling receptor-mediated processes with dioxin: implications for pharmacokinetics and risk assessment.
M. Andersen (1993)
10.1016/0378-4274(93)90123-F
Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing.
H. Clewell (1993)
10.1006/TAAP.1993.1096
A mechanistic model of effects of dioxin on gene expression in the rat liver.
M. Kohn (1993)
10.1016/0887-2333(94)90002-7
Relevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics.
J. Houston (1994)
10.1006/FAAT.1994.1059
A Partition Coefficient Determination Method for Nonvolatile Chemicals in Biological Tissues
G. Jepson (1994)
10.1111/J.1539-6924.1994.TB00268.X
Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride.
H. Clewell (1994)
10.1080/15287399509532021
An algorithm for predicting tissue: blood partition coefficients of organic chemicals from n-octanol: water partition coefficient data.
P. Poulin (1995)
10.1177/074823379501100505
An Approach for Incorporating Tissue Composition Data Into Physiologically Based Pharmacokinetic Models
M. Pelekis (1995)
10.1177/096032719501400307
A biologically-based algorithm for predicting human tissue: blood partition coefficients of organic chemicals
P. Poulin (1995)
10.1016/0300-483X(96)03385-9
Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk.
H. Clewell (1996)
10.1016/S0300-483X(96)03546-9
A pharmacokinetic model describing pulsatile uptake of orally-administered carbon tetrachloride.
G. Semino (1997)
10.1177/074823379701300401
Physiological Parameter Values for Physiologically Based Pharmacokinetic Models
Ronald P. Brown (1997)
10.1016/S0190-9622(97)70063-X
A physiologically based pharmacokinetic model for retinoic acid and its metabolites.
H. Clewell (1997)
10.3109/03602539709002237
Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices.
J. Houston (1997)
10.1146/ANNUREV.PHARMTOX.38.1.461
Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport.
K. Ito (1998)
10.2165/00002018-199920020-00005
Drug Interactions of HIV Protease Inhibitors
L. Malaty (1999)
10.1081/CUS-120001859
Mathematical models in percutaneous absorption
M. Roberts (1999)
10.2165/00003088-199936030-00003
Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations
T. Lavé (1999)
10.1002/(SICI)1520-6017(200001)89:1<16::AID-JPS3>3.0.CO;2-E
A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery.
P. Poulin (2000)
10.2174/1389200003339018
Early ADME in support of drug discovery: the role of metabolic stability studies.
T. Thompson (2000)
10.1002/JPS.1120
Pharmacokinetic models of dermal absorption.
K. D. McCarley (2001)
10.1016/S0169-409X(01)00179-X
Predicting the impact of physiological and biochemical processes on oral drug bioavailability.
B. Agoram (2001)
10.1007/s00228-001-0405-6
Estimating the starting dose for entry into humans: principles and practice
B. Reigner (2001)
10.1002/1520-6017(200104)90:4<436::AID-JPS1002>3.0.CO;2-P
Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs.
P. Poulin (2001)
10.1016/S1367-5931(00)00228-3
Prediction of pharmacokinetic properties using experimental approaches during early drug discovery.
P. Chaturvedi (2001)
10.2165/00003088-200140070-00006
Prediction of Hepatic Metabolic Clearance
J. Zuegge (2001)
10.1002/JPS.10128
Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
P. Poulin (2002)
10.1016/S0928-0987(02)00132-X
Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA.
N. Parrott (2002)
10.1002/JPS.10005
Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.
P. Poulin (2002)
10.1093/TOXSCI/69.1.60
Development of a physiologically based pharmacokinetic model for estradiol in rats and humans: a biologically motivated quantitative framework for evaluating responses to estradiol and other endocrine-active compounds.
D. Plowchalk (2002)
10.2165/00003088-200342100-00002
Whole Body Pharmacokinetic Models
I. Nestorov (2003)
10.1038/NRD1032
ADMET in silico modelling: towards prediction paradise?
H. van de Waterbeemd (2003)
10.1016/S0378-4274(02)00374-0
Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection.
Frank-Peter Theil (2003)
10.2174/1568026033452096
The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery.
J. Lin (2003)
10.1093/TOXSCI/KFG001
Physiological modeling of inhalation kinetics of octamethylcyclotetrasiloxane in humans during rest and exercise.
M. Reddy (2003)
10.1002/JPS.10461
Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans.
O. Luttringer (2003)
10.1023/A:1012036324237
The Use of Human Hepatocytes to Select Compounds Based on Their Expected Hepatic Extraction Ratios in Humans
T. Lave (2004)
10.1023/A:1023525513696
Clinical Pharmacokinetic/Pharmacodynamic and Physiologically based Pharmacokinetic Modeling in New Drug Development: The Capecitabine Experience
K. Blesch (2004)
10.1023/B:PHAM.0000003373.72652.c0
A Physiologic Model for Simulating Gastrointestinal Flow and Drug Absorption in Rats
S. Willmann (2004)
10.1126/SCIENCE.1096361
The Many Roles of Computation in Drug Discovery
W. L. Jorgensen (2004)
10.1023/A:1010994022294
Optimizing Drug Development: Strategies to Assess Drug Metabolism/Transporter Interaction Potential—Toward a Consensus
G. Tucker (2004)
10.1023/A:1018943613122
Physiological Parameters in Laboratory Animals and Humans
B. Davies (2004)
10.1023/A:1023272707390
Lumping of Whole-Body Physiologically Based Pharmacokinetic Models
I. Nestorov (2004)
10.1002/0471478768.CH1
Introduction: A Historical Perspective of the Development and Applications of PBPK Models
M. Andersen (2005)
10.1002/0471478768.CH14
Dermal Exposure Models
M. Reddy (2005)
10.1111/J.1742-7843.2005.PTO960308.X
Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man.
N. Parrott (2005)
10.1002/JPS.20419
An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery.
N. Parrott (2005)
10.1002/0471478768.CH9
Metals and Inorganic Compounds
J. Campain (2005)
10.1002/JPS.20322
Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.
Trudy Rodgers (2005)
10.1002/CBDV.200590119
Development and Application of Physiologically Based Pharmacokinetic‐Modeling Tools to Support Drug Discovery
Christian Lüpfert (2005)
10.1124/dmd.105.004259
A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES
R. Riley (2005)
10.1007/BF01059734
A review of the applications of physiologically based pharmacokinetic modeling
K. Himmelstein (2005)
10.1007/BF01066325
The use and abuse of models
A. Rescigno (2005)
10.1007/BF01059667
Animal scale-up
R. Dedrick (2005)
10.1007/s10928-005-0004-8
Reducing Whole Body Physiologically Based Pharmacokinetic Models Using Global Sensitivity Analysis: Diazepam Case Study
I. Gueorguieva (2005)
10.1111/J.1365-2125.2005.02560.X
Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed.
L. Aarons (2005)
10.1007/BF01062545
In vitro andin vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models
J. Lin (2005)
10.1016/J.CBPA.2006.06.024
Genomic approaches to drug discovery.
D. Ricke (2006)
10.2165/00003088-200645050-00006
A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics
H. Jones (2006)
10.1517/17425255.2.4.619
Integrating invitro ADMET data through generic physiologically based pharmacokinetic models
D. Leahy (2006)
10.1002/JPS.20502
Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions.
Trudy Rodgers (2006)
10.2174/138955706778195153
In vitro ADME medium/high-throughput screening in drug preclinical development.
A. Lahoz (2006)
10.1007/BF02354273
Physiologically based pharmacokinetic modeling as a tool for drug development
S. B. Charnick (2006)
10.1016/J.IJPHARM.2005.11.002
Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability.
H. Cai (2006)
10.1124/dmd.105.004804
APPLICATION OF A GENERIC PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO THE ESTIMATION OF XENOBIOTIC LEVELS IN RAT PLASMA
F. Brightman (2006)
10.2174/138920007779315053
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.
Z. Barter (2007)
10.1208/ps060106
Physiologically based pharmacokinetics in Drug Development and Regulatory Science: A workshop report (Georgetown University, Washington, DC, May 29–30, 2002)
M. Rowland (2008)



This paper is referenced by
Evaluation of a Physiologically Based Pharmacokinetic (PBPK) Model Used to Develop Health Protective Levels for Trichloroethylene
T. Covington (2017)
10.1007/s11095-017-2218-z
Benchmarking of Human Dose Prediction for Inhaled Medicines from Preclinical In Vivo Data
T. Ericsson (2017)
10.1007/s40005-017-0307-y
Mechanistic understanding of the effect of renal impairment on metformin oral absorption using computer simulations
M. Almukainzi (2017)
10.1016/j.taap.2017.04.002
Combining transcriptomics and PBPK modeling indicates a primary role of hypoxia and altered circadian signaling in dichloromethane carcinogenicity in mouse lung and liver
M. Andersen (2017)
Toxicological profile for 1-Bromopropane
N. Roney (2017)
Toxicological profile for parathion
S. Keith (2017)
10.1016/B978-0-12-801406-6.00006-6
Nanoparticle Pharmacokinetics and Toxicokinetics
Ashutosh Kumar Singh (2016)
10.3934/mbe.2016.13.119
A physiologically-based pharmacokinetic model for the antibiotic ertapenem.
M. Joyner (2016)
Draft toxicological profile for JP-5, JP-8, and jet A fuels
J. Risher (2016)
10.5772/65361
Computational Fluid-Particle Dynamics Modeling for Unconventional Inhaled Aerosols in Human Respiratory Systems
Y. Feng (2016)
Development of a toxicokinetic model for the honey bee (Apis mellifera) colony for the use in risk assessment
K. Hörig (2016)
10.1007/978-3-319-75408-6_38
Fuzzy Physiologically Based Pharmacokinetic (PBPK) Model of Chloroform in Swimming Pools
R. Dyck (2016)
10.1016/J.JAEROSCI.2015.12.008
The evolution of inhaled particle dose modeling: A review
R. Phalen (2016)
10.1021/acs.chemrestox.5b00341
Physicologically Based Toxicokinetic Models of Tebuconazole and Application in Human Risk Assessment.
Svava Ósk Jónsdóttir (2016)
Formulation and topical delivery of niosomes and proniosomes containing carnosine
Martha Maria Lundie (2016)
10.1016/j.taap.2014.10.014
An integrated QSAR-PBK/D modelling approach for predicting detoxification and DNA adduct formation of 18 acyclic food-borne α,β-unsaturated aldehydes.
R. Kiwamoto (2015)
Physiologically based in silico modelling to examine DNA adduct formation by different food-borne a,ß-unsaturated aldehydes at realistic low dietary exposure levels
R. Kiwamoto (2015)
10.1111/jvp.12145
Toxicokinetics and absolute oral bioavailability of melamine in broiler chickens.
S. Poapolathep (2015)
10.1016/j.toxlet.2014.06.026
Biological monitoring guidance values for chemical incidents.
John Cocker (2014)
10.14573/altex.1310011
Correlating in vitro data to in vivo findings for risk assessment.
A. S. Bale (2014)
Understanding temporality in human concentrations of organic contaminants -Considering human concentrations over time and through life in perspective of historic production and use
T. Nøst (2014)
10.1002/jps.24011
Predicting passive and active tissue:plasma partition coefficients: interindividual and interspecies variability.
Christopher D. Ruark (2014)
10.1124/dmd.112.049312
Species Differences in Biliary Clearance and Possible Relevance of Hepatic Uptake and Efflux Transporters Involvement
K. Grime (2013)
Développement de modèles prédictifs de la toxicocinétique de substances organiques
T. Peyret (2013)
INVESTIGATIONS ON VENTILATION EQUATION STRUCTURE IN PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF INHALED TOXICANTS
K. Yokley (2013)
10.5772/54965
Physiologically Based Pharmacokinetic Modeling: A Tool for Understanding ADMET Properties and Extrapolating to Human
M. Reddy (2013)
10.1016/j.yrtph.2013.03.005
Case study illustrating the WHO IPCS guidance on characterization and application of physiologically based pharmacokinetic models in risk assessment.
M. E. Meek (2013)
10.1155/2012/852384
Cutting Edge PBPK Models and Analyses: Providing the Basis for Future Modeling Efforts and Bridges to Emerging Toxicology Paradigms
J. Caldwell (2012)
10.3389/fphys.2012.00462
Modeling Drug- and Chemical-Induced Hepatotoxicity with Systems Biology Approaches
S. Bhattacharya (2012)
10.1080/15287394.2011.625548
Age-Specific Absolute and Relative Organ Weight Distributions For B6C3F1 Mice
Dale J Marino (2012)
10.1007/978-3-642-29265-1_3
Legislative Measures for In Vitro–In Vivo Correlations and Pharmacokinetic Modeling
V. Pillay (2012)
10.1007/s10928-012-9252-6
Use of partition coefficients in flow-limited physiologically-based pharmacokinetic modeling
M. D. Thompson (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar